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2072A Polypill Strategy to Improve Adherence
Results From the FOCUS ProjectABSTRACTBACKGROUND Adherence to evidence-based cardiovascular (CV) medications after an acute myocardial infarction (MI)
is low after the ﬁrst 6 months. The use of ﬁxed-dose combinations (FDC) has been shown to improve treatment
adherence and risk factor control. However, no previous randomized trial has analyzed the impact of a polypill strategy
on adherence in post-MI patients.
OBJECTIVES The cross-sectional FOCUS (Fixed-Dose Combination Drug for Secondary Cardiovascular Prevention)
study (Phase 1) aimed to elucidate factors that interfere with appropriate adherence to CV medications for secondary
prevention after an acute MI. Additionally, 695 patients from Phase 1 were randomized into a controlled trial (Phase 2) to
test the effect of a polypill (containing aspirin 100 mg, simvastatin 40 mg, and ramipril 2.5, 5, or 10 mg) compared with
the 3 drugs given separately on adherence, blood pressure, and low-density lipoprotein cholesterol, as well as safety and
tolerability over a period of 9 months of follow-up.
METHODS In Phase 1, a 5-country cohort of 2,118 patients was analyzed. Patients were randomized to either the polypill
or 3 drugs separately for Phase 2. Primary endpoint was adherence to the treatment measured at the ﬁnal visit by the
self-reported Morisky-Green questionnaire (MAQ) and pill count (patients had to meet both criteria for adherence at the
in-person visit to be considered adherent).
RESULTS In Phase 1, overall CV medication adherence, deﬁned as an MAQ score of 20, was 45.5%. In a multivariable
regression model, the risk of being nonadherent (MAQ <20) was associated with younger age, depression, being on a
complex medication regimen, poorer health insurance coverage, and a lower level of social support, with consistent
ﬁndings across countries.
In Phase 2, the polypill group showed improved adherence compared with the group receiving separate medications
after 9 months of follow-up: 50.8% versus 41% (p ¼ 0.019; intention-to-treat population) and 65.7% versus 55.7%
(p ¼ 0.012; per protocol population) when using the primary endpoint, attending the ﬁnal visit with MAQ ¼ 20 and high
pill count (80% to 110%) combined, to assess adherence. Adherence also was higher in the FDC group when measured by
MAQ alone (68% vs. 59%, p ¼ 0.049). No treatment difference was found at follow-up in mean systolic blood pressure
(129.6 mm Hg vs. 128.6 mm Hg), mean low-density lipoprotein cholesterol levels (89.9 mg/dl vs. 91.7 mg/dl), serious
adverse events (23 vs. 21), or death (1, 0.3% in each group).
CONCLUSIONS For secondary prevention following acute MI, younger age, depression, and a complex drug treatment
plan are associated with lower medication adherence. Meanwhile, adherence is increased in patients with higher
insurance coverage levels and social support. Compared with the 3 drugs given separately, the use of a polypill strategy
met the primary endpoint for adherence for secondary prevention following an acute MI. (Fixed Dose Combination
Drug [Polypill] for Secondary Cardiovascular Prevention [FOCUS]; NCT01321255) (J Am Coll Cardiol 2014;64:2071–82)
© 2014 by the American College of Cardiology Foundation.M ortality due to cardiovascular diseases(CVDs) is still rising in low- and middle-income countries (LMIC), and is expected
to surpass communicable diseases as the leading
cause of death by 2030 (1). In high-income countries,
however, CVD mortality rates are stable or even
decreasing, mainly due to the appropriate adminis-
tration of evidence-based drug treatments (e.g., sta-
tins, antihypertensive and antithrombotic agents) inpatients at high risk, particularly those recovering
from an acute coronary event (2). It has been esti-
mated that one-half of the overall reduction in CVD
mortality observed over the past 20 years in western
countries could be attributed to appropriate use of
cardiovascular (CV) medications for secondary pre-
vention (3).
Despite these advances, signiﬁcant evidence high-
lights the existence of a gap in drug treatment and
AB BR E V I A T I O N S
AND ACRONYM S
ACEI = angiotensin-converting
enzyme inhibitor
ARB = angiotensin-II receptor
blocker
ASA = acetylsalicylic acid
BP = blood pressure
CV = cardiovascular
LDL-C = low-density
lipoprotein cholesterol
LMIC = low- and middle-
income countries
MAQ = Morisky-Green
medication adherence
questionnaire
MI = myocardial infarction
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2073room for improvement in secondary prevention. On a
global scale, data from the PURE (Prospective Urban
Rural Epidemiology) study showed that among
participants with a history of coronary heart disease
or stroke, only 25% were taking antiplatelet drugs,
17% were taking beta-blockers, 20% were taking
angiotensin-converting enzyme inhibitors (ACEIs) or
angiotensin-II receptor blockers (ARBs), and 15%
were taking statins 5 years post-event. Considering
only LMIC, the use of these drugs was found to be
as low as 3% in the same study (4). In developed
countries, the situation, although better, is still
worrisome. For instance, in Europe, the EUROASPIRE
study, a survey of coronary patients in 22 countries,
showed that among participants with prior coronary
artery disease (68% with myocardial infarction
[MI], all comers), in spite of appropriate prescrip-
tion of secondary CV medication, 56% of patients
persisted with hypertension and 51% with hyper-
cholesterolemia (5).SEE PAGE 2083Lack of compliance with prescribed lifestyle modi-
ﬁcation and lack of medication adherence, deﬁned as
the extent to which patients follow the instructions
they are given for prescribed treatments, are also
fundamental factors affecting the strategies for CVD
secondary prevention. It has been estimated that
adherence to CV medications is about 57% after a
median of 2 years (6). It is generally recognized
that adherence is determined by the interplay of
5 “dimensions”: socioeconomic, medication-related,
condition-related, health system-related, and patient-
related factors (7). Among the number of factors asso-
ciated with these dimensions, poor availability and
affordability of medication are considered critical
in emerging countries (8), but overall, the complexity
of treatment and the daily number of prescribed
pills have been repeatedly recognized as the most
important factors responsible for lack of adherence
to treatment (9,10).
To address these determinants of poor adherence, a
strategy based on the use of a ﬁxed-dose combination
(FDC) or polypill, including key medications to reduce
CV risk as a once daily dose pill, has been recently
introduced. Several trials have tested the effect of
such an approach on adherence (measured in various
self-reported ways) in high-risk patients including
those with established CV disease with promising
results (11–13). To date, however, no trial has studied
the effect of an FDC strategy on adherence in second-
ary prevention using direct measures in addition to
self-report. The FOCUS (Fixed Dose Combination Drug
for Secondary Cardiovascular Prevention) project wasdesigned, using an appropriate conceptual
framework, to better understand the adher-
ence to medication in the post-MI setting, the
factors that inﬂuence the lack of adherence,
and the effect of an FDC on adherence in this
high-risk population.
METHODS
The protocol for the FOCUS study, which was
funded by the 7th Framework Programme of
the European Commission, has been previ-
ously described (14). FOCUS consists of 2
concurrent but sequential phases. Phase 1 is a
multicountry comprehensive analysis of fac-
tors that determine the appropriate use of CV
prevention interventions, particularly socio-
economic and comorbid factors. Phase 2 is a ran-
domized, controlled clinical trial testing the effect of
an FDC, the CNIC-FS-FERRER polypill containing
acetylsalicylic acid (ASA) 100 mg, simvastatin 40 mg,
and ramipril 2.5, 5, or 10 mg, on adherence and con-
trol of CV risk factors. The local ethical committees
and the health authorities in the participating coun-
tries approved the protocol.
PHASE 1. Rat iona le . FOCUS Phase 1 was designed as
an observational, prospective, cross-sectional study
to assess the relationship of a variety of factors—
including socioeconomic, clinical, and psychosocial
factors—to patients’ adherence to treatment in 5
different countries (Argentina, Brazil, Italy, Paraguay,
and Spain). In addition to patients’ information, data
regarding the national health systems and various
economic indicators for each country were also
registered, including accessibility, cost, and afford-
ability of the standard drugs for secondary CV pre-
vention (ASA, statin, ACEI, and beta-blocker). Data at
the national level on economic development were
obtained from the World Bank as well as from the
Panamerican Health Organization (a yearly updated
database on health-related data), which included
gross internal product as well as other indicators
such as literacy rate, gross national income adjusted
for international dollars, percent of population under
national and international poverty line, percent of
unemployment on a given year, and inﬂation rate
(Online Appendix, Annex 1).
A research network linking 3 institutions was
established to carry out the study: the Istituto di
Ricerche Farmacologiche “Mario Negri” (IRFMN) in
Milan (Italy), the Instituto Damic in Buenos Aires
(Argentina), and the Fundació Clinic per la Recerca
Biomèdica in Barcelona (Spain). These institutions
Morisky
V1 V2 V3
9M4M1M0
Pill Count
FIGURE 1 Visiting Schema Phase 2
The FOCUS trial included various visits during the 9-month
follow-up period in which adherence was measured using
Morisky Green Adherence Questionnaire and pill count.
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and Paraguay and another 38 in Italy and Spain
(Online Appendix, FOCUS Investigators). Sites were
selected so as to include patients from widely
differing socioeconomic strata. The Centro Nacional
de Invetigaciones Cardiovasculares (CNIC) in Madrid
(Spain) functioned as the coordinating center for the
overall study.
Sample s ize . A total of 2,000 subjects had to be
included in the study, 1,000 in Europe and 1,000 in
South America. With this sample size, a 2-sided 95%
conﬁdence interval for a single proportion using the
large sample normal approximation would extend
1.5% from the observed proportion for an expected
proportion of 50%.
Pat ient se lect ion . The study population included
men and women age $40 years with a history of
acute MI within the last 2 years. After signing the
informed consent, data was recorded in appropriate,
speciﬁcally-designed forms derived from the manual
developed by the World Health Organization/Health
Action International for the Medicine Prices survey
(15). All variables were collected in a single visit. Due
to slow recruitment, after the initial 591 participants
had been included, an amendment to the initial
protocol was approved to allow for the inclusion of
patients with any past history of an acute MI,
regardless of duration from enrollment. Exclusion
criteria were as follows: contraindication for any of
the FDC components, residence in a nursing home, or
having a mental illness that limits the capacity for
self-care.
Pr imary endpoint . FOCUS Phase I included 3
primary outcomes: 1) to assess the proportion of
patients with no contraindications who were pre-
scribed aspirin, ACEIs, beta-blockers, and statins;
2) to calculate adherence to those medications using
the Morisky-Green medication adherence question-
naire (MAQ); and 3) to identify factors contributing
to inadequate adherence to treatment.
Est imat ion of adherence . The MAQ is a self-
reported questionnaire with 4 questions:
1. Some people forget to take their medications. How
often does this happen to you?
2. Some people miss out a dose of their medication or
adjust it to suit their own needs. How often do you
do this?
3. Some people stop taking their medication when
they feel better. How often do you do this?
4. Some people stop taking their medication when
they feel worse. How often do you do this?
Each question is scored 1 to 5 according to the
possible answers (always, very frequently, frequently,not very frequently, or never). Total score number
may range from 4 to 20 with higher scores indicating
higher levels of reported adherence. Although it is
generally accepted that a MAQ score $16 identiﬁes
good adherence (16), (initially planned in the proto-
col), most previous studies have used a single
yes/no answer to each question on self-reported use
of medications to evaluated adherence (11–13), a
method that might be better and is comparable to
the MAQ score of 20 used in our study.
Access ib i l i ty and affordab i l i ty of medicat ion .
Availability was deﬁned as “percentage of facilities
(hospitals, pharmacy ofﬁces) in which the medicines
were available at the time of survey.” To calculate
availability, a telephone survey was carried out in 146
pharmacies located within 500 m of each partici-
pating site (49 in Argentina, 40 in Italy, 31 in Spain,
20 in Brazil, and 6 in Paraguay). Affordability was
calculated as the number of days’ wages the lowest-
paid government worker would be required to pay
for purchasing from the private sector a 1-month
course of medication.
PHASE 2. Phase 2 was designed as a randomized,
open-label, active-controlled, piggyback, 2-group
parallel trial. The overall aim of Phase 2 was to
assess the efﬁcacy, safety, and efﬁciency of the CNIC-
FS-Ferrer polypill, an FDC pill containing ASA (100
mg), simvastatin (40 mg), and Ramipril at 3 different
doses (2.5, 5, or 10 mg, which allowed for up-titration
at the discretion of the physician), on increasing
adherence, as well as reducing blood pressure (BP)
and low-density lipoprotein cholesterol (LDL-C) after
9 months of follow-up.
Sample s ize for Phase 2 . To detect a 14%
improvement in adherence compared with the stan-
dard control group (expected around 50%), with
type I error of 0.025 and 80% power, 251 patients in
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2075each group were needed. This was increased to 335
per group to allow for a drop-out rate of 25%.
Study protoco l . Patients previously included in
Phase 1 and without exclusion criteria were invited
to participate in Phase 2. Exclusion criteria for
Phase 2 were: secondary dyslipidemia, contraindi-
cation to any of the components of the polypill,
participation in another trial, previous percutaneous
transluminal coronary angioplasty with a drug-
eluting stent within the previous year, severe
congestive heart failure (New York Heart Associa-
tion functional class III to IV), serum creatinine >2
mg/dl, any condition limiting life expectancy <2
years, and pregnancy or pre-menopause. After
signing the informed consent, a central electronic
randomization service assigned participants to 1 of 2
arms: the FDC polypill, or the 3 drugs (ASA, ram-
ipril, and simvastatin) separately. Both the FDC pill
and the conventional treatment were provided
freely for the study. The FDC polypill was admin-
istered once daily, as were the 3 active substances
given separately. After the ﬁrst visit (inclusion/
randomization), patients were followed at 1, 4, and
9 months to assess clinical status, detect potential
adverse events, titrate ramipril dosage, count
number of pills, and provide medication (Figure 1).
The number of pills provided at each visit varied
randomly to avoid patients’ manipulation and to
optimize adherence assessment. A total of 38 sites
in 2 countries in Europe (Italy and Spain) and 25
sites in 2 countries in South America (Argentina
and Paraguay) participated in FOCUS phase 2
(Online Appendix, Annex 2).
The study was conducted in accordance with Good
Clinical Practice. All appropriate national regulatory
authorities and ethics committees of the participating
sites approved the study. All patients participated
voluntarily in the study after signing informed
consent.
Est imat ion of adherence . Similar to Phase 1,
FOCUS Phase 2 used the indirect self-reported MAQ to
estimate adherence, but also used pill count as a
direct measurement of adherence. All medication
boxes were labeled and numbered to facilitate
auditing of dispensed and returned medication. Each
patient received a quantity of pills exceeding the
number required before the next visit. Patients were
instructed to return all boxes and surplus medica-
tion. Pill count was calculated as: (no. of pills
dispensed  no. of pills returned)/number of pills
prescribed  100. A pill count between 80% and 110%
was considered good adherence. For statistical anal-
ysis, adherence was considered as a dichotomous
variable. Patients were considered to be “adherent”if they achieved good adherence scores with both
methods—pill count and MAQ.
Endpoints and outcomes . The Phase 2 primary
outcome was percentage of patients taking medica-
tion adequately at 9 months in each arm assessed by
attendance at the ﬁnal 9-month visit and the MAQ
and pill count methods, simultaneously. Patients lost
for follow-up and those discontinuing medication
due to adverse effects were also considered to be
nonadherent for this analysis.
Secondary outcomes of Phase 2 included: risk
factor control in each study arm (BP and lipid LDL-C
levels at months 1 and 9), incidence of adverse
events (including death, reinfarction, and rehospi-
talization for any CV cause), rate of treatment with-
drawal, tolerability, and quality of life, as well as
economic endpoints (medical and nonmedical costs,
data not shown).
STATISTICAL ANALYSIS. Phase 1 descriptive anal-
yses are based on means and SDs for continuous
variables and counts and proportions for categorical
variables. Differences between groups were tested by
t-tests for continuous variables or chi-square for
binary variables. A model for the determinants of
adherence used a binary outcome (MAQ score 20 yes/
no) and forward stepwise regression forcing country
into the model.
For Phase 2, country-adjusted logistic models were
used to study adherence to treatment following
intention-to-treat assumptions. Furthermore, a sen-
sitivity analysis was carried out using 458 patients
with complete data at every visit. For the study of
systolic/diastolic BP and LDL-C, analysis of covari-
ance models were ﬁtted using baseline values as a
covariate. Statistical analyses were conducted using
STATA version 12 (Stata Corp. 2011, College Station,
Texas). Differences were considered statistically sig-
niﬁcant at a 2-sided p value <0.05.
RESULTS
PHASE 1. Basel ine characterist ics of part ic ipants.
A total of 2,118 patients with a history of MI who met
the inclusion and exclusion criteria were enrolled
between January 2011 and January 2014 (761 in Spain,
654 in Italy, 528 in Argentina, 113 in Brazil, and 62 in
Paraguay). Patient baseline characteristics by country
and overall are shown in Table 1. Baseline patient
characteristics categorized by adherence levels (using
MAQ ¼ 20) are shown in Online Table 1. Mean age
at enrollment was 64.1 years and mean time from the
index MI was 3.5 years.
Proportion of post-MI patients receiving appropriate
secondary prevention. Table 2 shows reported use of
TABLE 1 Baseline Characteristics of Patients Included in Phase 1, By Country and Overall
Overall Argentina Brazil Paraguay Italy Spain
n (%) 2,118 528 (24.93) 113 (5.34) 62 (2.93) 654 (30.9) 761 (35.93)
Characteristics
Male 1,700 (80.26) 437 (82.8) 81 (71.7) 49 (79.0) 491 (75.1) 642 (84.4)
Age, yrs 64.01  11.28 60.4  10.3 62.3  10.4 61.5  9.08 67.2  11.4 64.2  11.4
#50 262  12.37 93  17.9 13  11.5 8  12.9 50  7.66 98  13.1
51–70 1,220  57.6 342  65.6 72  63.7 43  69.4 341  52.2 422  56.4
>70 615  29.04 86  16.5 28  24.8 11  17.7 262  40.1 228  30.5
Clinical
Age at date of AMI 60.45  11.27 57.7  10 61.2  10.6 61.3  9.05 63.3  11.5 59.6  11.6
Previous AMI history 281 (13.27) 67 (12.8) 22 (19.5) 14 (22.6) 96 (14.7) 82 (12.1)
Previous angina history 612 (28.9) 205 (39.1) 33 (29.2) 35 (56.5) 206 (31.5) 133 (19.6)
Previous syncope history 94 (4.44) 13 (2.49) 8 (7.08) 0 (0) 55 (8.41) 18 (2.65)
Previous ventricular tachycardia 94 (4.44) 17 (3.24) 5 (4.42) 2 (3.23) 44 (6.73) 26 (3.82)
Previous pacemaker 46 (2.17) 6 (1.15) 0 (0) 0 (0) 28 (4.28) 12 (1.76)
Previous ICD 46 (2.17) 9 (1.72) 1 (0.885) 0 (0) 20 (3.06) 16 (2.38)
Previous hypertension history 1,328 (62.7) 364 (69.5) 84 (74.3) 44 (71) 410 (62.7) 426 (60.9)
Previous dyslipidemia history 1,249 (58.97) 319 (60.9) 74 (65.5) 30 (48.4) 385 (58.9) 441 (63.0)
Previous diabetes history 554 (26.16) 119 (22.8) 35 (31.0) 19 (30.6) 159 (24.3) 222 (31.8)
Previous SBP, mm Hg 129.05  18.39 125  17.1 129  21.9 110  15.8 131  16.3 131  19.4
Previous DBP, mm Hg 75.93  10.04 75.6  9.86 77  12.7 67.9  8.71 78.5  8.37 74.3  10.6
Normal <120 or <80 mm Hg 464  21.91 144  27.5 34  30.1 39  62.9 86  13.3 161  22.7
Pre-hypertension 120–139 or
80–89 mm Hg
991  46.79 265  50.6 45  39.8 17  27.4 349  53.8 315  44.4
Hypertension 602  28.42 115  21.9 34  30.1 6  9.68 214  33 233  32.9
BMI, kg/m2 27.51  4.57 28  5.05 27.5  4.65 27.8  4.18 27  4.34 27.6  4.36
Normal (healthy weight) <25 kg/m2 618  29.18 149  28.7 40  35.4 15  24.2 235  36 179  27.2
Overweight from 25 to 30 kg/m2 890  42.02 211  40.6 44  38.9 34  54.8 285  43.6 316  48.1
Obese >30 kg/m2 497  23.47 160  30.8 29  25.7 13  21 133  20.4 162  24.7
s3 23 (1.09) 5 (0.954) 1 (0.885) 2 (3.23) 10 (1.53) 5 (0.711)
History of pulmonary disease 28 (1.32) 5 (0.954) 1 (0.885) 4 (6.45) 13 (1.99) 5 (0.711)
History of chronic disease 125 (5.9) 19 (3.63) 3 (2.65) 2 (3.23) 59 (9.02) 42 (5.96)
History of renal disease 102 (4.82) 19 (3.63) 6 (5.31) 2 (3.23) 47 (7.19) 28 (3.97)
History of cancer 78 (3.68) 7 (1.34) 2 (1.77) 0 (0) 27 (4.13) 42 (5.96)
Comorbidity 342 (16.15) 50 (9.47) 12 (10.6) 8 (12.9) 120 (18.3) 152 (20.0)
Socioeconomic
Distance to the nearest
medical center, km
5.9  21.7 10.4  37.4 3.8  6.8 5.5  8.8 6.7  14.1 1.5  4.5
#10 km 1,656  78.19 441  84.5 100  88.5 49  79 520  80 546  97.2
>10 km 253  11.95 81  15.5 13  11.5 13  21 130  20 16  2.85
% Insurance coverage 87.3 (30.71) 63.2 (46.9) 96.9 (13.8) 85.5 (35.5) 93.5 (17.2) 99.5 (6.7)
<50% 197 (9.3) 181 (34.9) 1 (0.885) 9 (14.5) 3 (0.459) 3 (0.45)
$50% 1,815 (85.69) 337 (65.1) 112 (99.1) 53 (85.5) 650 (99.5) 663 (99.5)
Educational level
Illiterate 59 (2.79) 5 (0.958) 5 (4.42) 0 (0) 18 (2.75) 31 (4.54)
Others 1,975 (93.25) 517 (99) 108 (95.6) 62 (100.0) 636 (97.2) 652 (95.5)
Occupation
Professionals 440 (20.77) 86 (16.4) 4 (3.57) 8 (12.9) 104 (15.9) 238 (34.7)
Others 1,597 (75.4) 438 (83.6) 108 (96.4) 54 (87.1) 549 (84.1) 448 (65.3)
Continued on the next page
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2076ASA, beta-blockers, statins, ACEIs, and ARBs both
overall and by country, and reveals high rates of
adequate prescription in a post-MI population ac-
cording to current guidelines.
Est imat ion of basel ine adherence . The degree of
adherence to prescribed medications was calculated
using the MAQ. Baseline adherence of the entirepopulation and by country is shown in Online Table 2.
When good adherence was deﬁned as an MAQ score
>16, >90% of patients were included in this category,
suggesting that this score overestimates adherence in
our population. Using 20 as the cut-off point to deﬁne
adherence, we found average baseline adherence
levels of 45.5%, in concordance with most published
TABLE 1 Continued
Overall Argentina Brazil Paraguay Italy Spain
Risk factors
Smoker 319 (15.06) 103 (19.9) 17 (15.0) 17 (27.4) 85 (13.0) 97 (14.0)
Former smoker 855 (40.37) 184 (35.5) 66 (58.4) 21 (33.9) 278 (42.6) 306 (44.1)
Family history of CV diseases 641 (30.26) 160 (30.5) 53 (46.9) 28 (45.2) 245 (37.5) 155 (22.3)
Sedentary 905 (42.73) 323 (61.6) 65 (57.5) 40 (64.5) 278 (42.5) 199 (28.6)
Alcohol 646 (30.5) 97 (18.6) 30 (26.5) 20 (32.3) 299 (45.7) 200 (28.7)
Baseline treatment
Aspirin 1,917 (90.51) 480 (97.2) 111 (99.1) 60 (100.0) 606 (92.9) 660 (95.4)
Antiplatelets 959 (45.28) 277 (56.0) 55 (49.1) 53 (88.3) 294 (45.1) 280 (40.1)
Statin 1,934 (91.31) 475 (96.5) 111 (99.1) 60 (100) 614 (94.3) 674 (97.1)
Beta-blocker 1,740 (82.15) 454 (92.1) 105 (93.8) 57 (96.6) 546 (83.9) 578 (84.4)
ACEI 1,370 (64.68) 370 (75.1) 78 (69.6) 46 (78.0) 469 (72.0) 407 (60.6)
ARB 337 (15.91) 87 (18.1) 29 (26.1) 8 (13.6) 93 (14.3) 120 (19.1)
Total number of pills (and others)/day 7.25  2.85 6.89  2.15 8.95  2.68 8.87  1.72 6.55  2.52 7.73  3.38
Depression
PHQ-9 score 5–9 minimal symptoms 661 (31.21) 0 (0) 0 (0) 0 (30.6) 311 (48.5) 350 (48.4)
PHQ-9 score 10–14 minor depression 936 (44.19) 215 (41) 41 (36.3) 19 (30.6) 311 (48.5) 350 (48.4)
PHQ-9 score 15–19 major depression,
moderately severe
693 (32.72) 194 (37) 31 (27.4) 22 (35.5) 208 (32.4) 238 (32.9)
PHQ-9 score $20 major depression, severe 435 (20.54) 116 (22.1) 41 (36.3) 21 (33.9) 122 (19.0) 135 (18.7)
Stress, yes 1,583 (74.74) 403 (76.5) 70 (61.9) 44 (71.0) 457 (70.1) 609 (81.6)
Center private 514 (24.27) 402 (81.2) 112 (100.0) 0 (0) 0 (0) 0 (0)
Center public 1,503 (70.96) 93 (18.8) 0 (0) 60 (100.0) 652 (100.0) 698 (100.0)
Cardiologist 1,663 (78.52) 495 (100.0) 0 (0) 60 (100.0) 652 (100.0) 456 (65.3)
General treatment 354 (16.71) 0 (0) 112 (100.0) 0 (0) 0 (0) 242 (34.7)
<4 pills 68 (3.21) 12 (2.42) 0 (0) 0 (0) 29 (4.45) 27 (3.87)
$4–9 pills 1,181 (55.76) 324 (65.5) 37 (33.0) 14 (23.3) 442 (67.9) 364 (52.1)
$10 pills 767 (36.21) 159 (32.1) 75 (67.0) 46 (76.7) 180 (27.6) 307 (44.0)
Complex treatment, yes 208 (9.82) 34 (6.87) 4 (3.57) 15 (25.0) 64 (9.82) 91 (13)
Time from AMI, months 42.96  66.93 33.8  63.9 15.5  16 2.17  4 45.9  68 54.9  72.4
<6 months 595 (28.09) 222 (50.2) 14 (12.8) 52 (88.1) 149 (26.3) 158 (28.0)
6 months to 1 yr 239 (11.28) 59 (13.3) 30 (27.5) 5 (8.47) 59 (10.4) 86 (15.2)
1–2 yrs 446 (21.06) 68 (15.4) 57 (52.3) 2 (3.39) 216 (38.1) 103 (18.2)
>2 yrs 462 (21.81) 93 (21.0) 8 (7.34) 0 (0) 143 (25.2) 218 (38.6)
Values are n (%) or mean  SD.
ACEI ¼ angiotensin-converting enzyme inhibitors; AMI ¼ acute myocardial infarction; ARB ¼ angiotensin-II receptor blockers; BMI ¼ body mass index; CV ¼ cardiovascular;
DBP ¼ diastolic blood pressure; ICD ¼ implantable cardioverter-deﬁbrillator; PHQ-9 ¼ Patient Health Questionnaire-9; SBP ¼ systolic blood pressure.
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in both FOCUS Phase 1 and 2.
Access ib i l i ty and affordab i l i ty . All facilities in all
countries had all 4 study drugs available at the time of
enquiry. Affordability ranged from 16.96 days mean
wages in Argentina to 0.65 in Spain (Paraguay 5.7,
Brazil 4.4, and Italy 0.72 days).
Factors that contr ibute to inadequate pat ient
adherence to t reatment . Online Appendix Annex 1
and Online Table 3 summarize the variables included
in the study and their association with adherence.
Patients younger than 50 years of age, those taking
more than 10 pills, those following a complex regimen
(e.g., those taking medications other than orally),
current smokers, and those with sedentary lifestyleswere signiﬁcantly more nonadherent. Importantly,
there was a signiﬁcant trend toward more non-
adherence with a higher score of depression (as
measured by the Patient Health Questionnaire-9). Of
the sociodemographic variables, illiteracy level, lower
social support, and lower percentage of insurance
coverage showed signiﬁcantly lower levels of
adherence. Lower levels of adherence were also noted
for those patients being treated by general practi-
tioners (as opposed to cardiologists) and those being
treated in a private center (as opposed to a public
health center).
To identify which were the key independent pre-
dictors of nonadherence, a forward stepwise regres-
sion procedure was used with country forced into the
TABLE 2 Percentages of Patients Receiving Secondary Prevention Medication,
by Country and Overall, in Phase 1
Patients
Included
in Phase 1 ASA Statin BB ACEI ARB
Argentina 528 486 (97.2) 481 (96.6) 460 (92.2) 376 (75.4) 88 (18.1)
Brazil 113 46 (100.0) 45 (97.8) 43 (93.5) 33 (71.7) 10 (21.7)
Paraguay 62 60 (100.0) 60 (100.0) 57 (96.6) 46 (78.0) 8 (13.6)
Italy 654 614 (91.6) 622 (93.0) 555 (83.0) 472 (70.6) 99 (14.8)
Spain 761 633 (94.9) 648 (96.9) 558 (84.5) 402 (62.2) 105 (17.6)
Overall 2,118 1,953 (94.9) 1,972 (95.8) 1,777 (86.7) 1,392 (68.4) 348 (17.7)
Values are n (%).
ASA ¼ acetyl salicylic acid; BB ¼ beta-blocker; other abbreviations as in Table 1.
TABLE 3
to Adhere
Age <50
Score dep
Score soci
% insuran
Complexit
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independently associated with younger age (younger
than age 50 years), scoring high on the depression
scale, and following a complex (administrations other
than oral) treatment. However, the odds of being
adherent increased with higher percentage of health
insurance coverage and with optimal levels of social
support.
PHASE 2. In Phase 2, a total of 695 patients were
enrolled from 4 countries during January 2011 to
September 2013. They were followed for 9 months.
Figure 2 shows the study ﬂow chart. In Phase 2, 695
patients were randomized: 345 to the control group
and 350 to the polypill. In the control group, 35 pa-
tients missed their 9-month visit (10.1%) versus 43
patients in the polypill arm (12.3%). All 695 patients
were included for the primary endpoint analysis
(percentage of patients taking medication adequately
at 9 months) in the intention-to-treat analysis. In
addition, the 458 patients attending all visits and
completing all data on adherence were analyzed in a
per-protocol analysis.
Effects on adherence . Intention-to-treat analysis
showed that after 9 months, 41% in the usual care
group and 50.8% in the polypill group were taking the
medication adequately (p ¼ 0.019). This difference
persisted after adjusting for the covariates showing
association with patients’ adherence in Phase 1. ForMultivariable Analysis of Variables That Independently Contribute
nce, Phase 1
Odds Ratio 95% Conﬁdence Interval p Value
yrs 1.50 1.08–2.09 0.015
ression 1.07 1.04–1.09 <0.001
al support 0.94 0.92–0.96 <0.001
ce coverage 1.00 0.99–1.00 0.025
y of treatment 1.42 1.00–2.02 0.047the 458 patients with complete data (per-protocol
analysis) 55.7% in the control group and 65.7% in the
polypill group were taking medication adequately
(p ¼ 0.012). The Central Illustration and Table 4 show
various measures of the patients’ adherence to
treatment in the study.
Effect of the polyp i l l on BP and LDL-C . There
were no differences in BP and cholesterol levels
between the control and FDC polypill groups at the
end of trial (Table 5).
Safety and tolerab i l i ty of the polyp i l l . There
were no signiﬁcant differences in adverse events in
both groups. A total of 32% of patients in the control
group and 35% in the polypill group suffered an
adverse event. In 6.6% of the control group and 6% of
the FDC group, the adverse effect was considered
severe. Treatment was discontinued in 4% of patients
in each group (Table 6).
DISCUSSION
To the best of our knowledge, this is the ﬁrst study to
carry out an in-depth assessment of the factors that
contribute to nonadherence to evidence-based CV
medications in a post-MI cohort from various socio-
economic and demographic backgrounds. Moreover,
the FOCUS trial has used validated, direct, and indi-
rect measures of adherence to assess the impact of a
polypill strategy in secondary prevention.
Our study shows that adherence to CV medications
is a complex problem, and many different factors in-
ﬂuence adherence in various ways. The single most
important factor associated with poor adherence was
depression; but, lack of social support and complexity
of treatment also contributed signiﬁcantly to poor
adherence. The results also demonstrate that access
to polypill in patients with CVD improved adherence
signiﬁcantly by 22% (41% vs. 50.1% in control and
polypill groups, respectively) after a 9-month follow-
up. The difference persisted in the per-protocol
analysis and after adjusting for variables identiﬁed
in Phase 1 as independent predictors of patients’
adherence to treatment. There were no differences in
BP and LDL-C proﬁle between the polypill and control
groups. Finally, the number of severe adverse effects
was low and similar in both groups of treatment.
ASSESSMENT OF ADHERENCE TO PRESCRIBED
MEDICATIONS: AN UNRESOLVED ISSUE. There are
several issues that need to be considered when
interpreting results from adherence trials, particu-
larly the lack of a gold standard for measuring
adherence and the enormous amount of factors that
have been shown to play a role in patients’ adherence
722 patients screened for
Phase 2
695 patients randomized
Phase 2
350 Randomized to Polypill 345 Randomized to Usual Care
293 attending
Visit 3
301 attending
Visit 3
44 did not attend visit 3
Lost to follow up (35)
DC due to AE (13)


57 did not attend visit 3
Lost to follow up (43)
DC due to AE (14)

FIGURE 2 Study Flow Chart in Phase 2
AE ¼ adverse effect(s); DC ¼ discontinued.
Castellano, J.M. et al. J Am Coll Cardiol. 2014; 64(20):2071–82.
CENTRAL ILLUSTRATION Effect of a Polypill Strategy on Adherence in
Secondary Cardiovascular Prevention
Adherence to treatment in post-myocardial infarction patients receiving a ﬁxed-dose
combination polypill versus those with conventional treatment (3 drugs given separately)
in Phase 2: (A) primary outcome measure (Visit þ Morisky-Green questionnaire [MAQ] ¼
20 þ pill count >80% to 110%); (B) using MAQ; and (C) adherence to treatment using
MAQ and pill count. ITI ¼ intention-to-treat.
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that have been developed to measure medication
adherence. The main advantage of these instruments
is that they are generally brief and inexpensive, they
provide immediate feedback to the clinician or
researcher, and the responses may help identify some
correctable misperceptions about adherence to med-
ications. However, despite their relative simplicity,
these scales are at best moderately related to objec-
tive measures of adherence and are limited by social
desirability and other recall biases. These biases lead
the instruments to overestimate how well patients
adhere by approximately 20% as compared with
objective measures.
The results of FOCUS Phase 1 demonstrated that
the MAQ score can overestimate adherence when a
cut-off of 16 is used, probably because in addition to
the patient overestimation, the physician quantiﬁca-
tion (evaluation) introduces a second source of
overestimation. Therefore, we used a cut-off of 20. A
score of 20 identiﬁes good adherers and scoring below
20 identiﬁes patients that are at some level non-
adherent to medication. This way to measure adher-
ence is similar to the ﬁrst option described in the
previous text, but due to the fact that it identiﬁes
perfect adherent behavior, it probably counterbal-
ances for some of the indirect overestimation
inherent to the methodology.
FACTORS THAT DETERMINE ADHERENCE. The
results from our study describe a very clear picture of
how these variables inﬂuence adherence and are in
agreement with previous ﬁndings. The single most
important factor that associates with poor adherence
is depression, which has repeatedly been identiﬁed in
the literature with low levels of patient adherence
(17–19).
Recent evidence shows that adherence to treat-
ment for certain chronic diseases decreases sig-
niﬁcantly during the ﬁrst 6 months after the
prescription (20). Contrary to these data, our study
found reasonable levels of adherence at baseline. We
believe that this is the consequence of an inclusion
bias secondary to the amendment that allowed the
inclusion of patients with any time from the original
MI. By extending the inclusion of patients based on
the time from the event, inclusion was biased toward
patients who were alive (due in part to being
adherent to medications), as well as compliance with
the visit schedule at the recruiting center (and
therefore, in turn, more likely to be adherent as well).
Although our results are in line with most of the
available data, including the critical role of depres-
sion and social support on patients’ adherence, the
fact that “number of pills” was not selected by the
TABLE 4 Differences in Adherence Using MAQ and Pill Count, Primary Endpoint
in Phase 2
Control Polypill p Value
Intention-to-treat
9-month visit þ pill count (80%–110%) þ
Morisky ¼ 20
n ¼ 345 n ¼350
Adherence 141 (41%) 178 (50.8%) 0.019
Per protocol
All visits þ pill count (80%–110%) þ
Morisky ¼ 20
n ¼ 219 n ¼ 239
Adherence 122 (55.7%) 157 (65.7%) 0.012
MAQ ¼ Morisky-Green questionnaire.
TABLE 5
Polypill T
Intention-
DSBP, m
DDBP, m
DLDL-C
Per-proto
DSBP, m
DDBP, m
DLDL-C
Values are c
BP ¼ bloo
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Several explanations have been considered: First, the
number of pills that FOCUS patients were taking is
very high, with a mean >7 and with 767 patients
taking more than 10 pills/day. Extremely high values
have been detected, with a considerable number of
patients taking up to 20 and 30 pills/day. Second, the
number of pills that the patients take daily is not
uniform and varies among countries. Most of these
extreme cases are patients recruited in Spain. Third,
the information provided by “number of pills” may be
provided also by other variables such as complexity of
treatment. In addition, we found that there was an
interaction between depression status and number of
pills. The relationship between number of pills and
poor adherence is evident only in patients without
depression.
IMPACT OF THE FDC ON ADHERENCE. The results of
FOCUS Phase 2 show that a polypill strategy in sec-
ondary prevention signiﬁcantly increased adherence
compared with the control group even in a highly-
adherent population at baseline. These results
should be considered in the context of previous trials
showing that FDCs improve adherence (11–13), which
found baseline adherence rates of 46% to 60% andChanges in Mean BP and Mean LDL-C Over 9 Months for
reatment and Control Groups, Phase 2
Control Polypill p Value
to-treat
m Hg 0.88 (0.76 to 2.53) 0.32 (2.02 to 1.38) 0.32
m Hg 0.38 (0.69 to 1.46) 0.11 (1.13 to 0.90) 0.51
, mg/dl 2.17 (0.96 to 5.29) 5.27 (0.31 to 10.86) 0.34
col
m Hg 0.63 (1.47 to 2.74) 0.97 (3.15 to 1.21) 0.30
m Hg 0.49 (0.86 to 1.85) 0.58 (1.91 to 0.74) 0.27
, mg/dl 2.90 (1.15 to 6.95) 5.13 (2.97 to 13.24) 0.64
hange in BP and LDL cholesterol, given in mm Hg and mg/dl.
d pressure; LDL ¼ low density lipoprotein; other abbreviations as in Table 1.improvements in adherence after randomization to
polypill to 70% to 85%. The FOCUS trial found
adherence levels at baseline of 59% (measured by
MAQ) and 59% (measured by MAQ and pill count
combined) with signiﬁcant increases at the end of the
study measured by MAQ alone and both MAQ and pill
count combined (68% and 65.7%, respectively). There
are various factors that potentially explain the dif-
ferences in magnitude of improved adherence. First,
the FOCUS trial had a shorter follow-up period than
other trials exploring the effect of a polypill strategy
on adherence, which had follow-up periods of 12 to
18 months. This is an important issue, as our results
show that, using the MAQ, the difference in adher-
ence on both groups seems to diverge the more time
goes by. Second, the different methods of measuring
adherence play a signiﬁcant role in the observed
results.
The FOCUS trial used more robust methods of
adherence (measurements in previous studies were
based on a single question on either whether the
patient could remember the name and dosage of
treatment to be classiﬁed as adherent—IMPACT
(IMProving Adherence using Combination Therapy)
[13]—or whether the patient had forgotten to take any
of the medication the week before—UMPIRE (Use of a
Multidrug Pill in Reducing cardiovascular Events)
[11] and KANYINI GAP (guidelines adherence with the
polypill) [12]). Even with seemingly simple methods
such as pill counts, adherence measurement is com-
plex, with issues concerning how to handle visits when
pills are not returned, apparent “over-adherence”
(>100% of expected pills for the interval between
visits), missed visits (when product is thus not
dispensed for a period), and protocol-speciﬁed time off
treatment. Moreover, pill count as a measure of
adherence has been shown to change pill taking
behavior and positively impact adherence itself, the so
called “pill count effect.” To this effect, a recent study
found a positive correlation between the number of
clinician pill counts and adherence. Patients were
divided into 3 groups (0 counts, 1 to 3 counts, and 4 to 7
counts) and exhibited adherence of 76%, 84%, and
92%, respectively (p ¼ 0.004) (21). Therefore, direct
measures of adherence (such as pill count) should be
taken with caution as they can affect adherence itself.
In our study, the pill count was performed for both the
group treated with polypill and the control group. By
performing pill count with 3 different drugs, it is
reasonable to expect a larger effect of the over-
estimation of pill counting on the control group.
Finally, most notably, FOCUS, unlike other trials,
provided both the polypill group and the control
group with free medications and an identical visit
TABLE 6 AEs Reported in Fixed-Dose Combination and
Usual Care Groups During the Trial, Phase 2
Control Polypill
Reported AE 112 (32.5) 124 (35.4)
Reported SAE 23 (6.6) 21 (6.0)
Patients interrupting treatment because
of AE
13 (3.7) 14 (4.0)
Death* 1 (0.3) 1 (0.3)
Reinfarction 2 (0.6) 2 (0.6)
Hospitalization 23 (6.7) 21 (6.0)
Hematological AE 6 (1.7) 5 (1.4)
Other cardiac AE† 4 (1.1) 10 (2.8)
Musculoskeletal AE 10 (3.8) 5 (1.4)
Cough 6 (1.7) 5 (1.4)
Dizziness 2 (0.6) 2 (0.6)
Hypotension 7 (0.2) 0 (0.0)
Values are n (%). *Control (cancer); polypill (trafﬁc accident). †Other cardiac AE:
for example, nonspeciﬁc angina.
AE ¼ adverse event(s).
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group was improved.
STUDY LIMITATIONS. This study had additional
limitations, as trials that are unavoidably unblinded
can have unintended differences between groups in
diagnostic and therapeutic intensity that are difﬁcult
to measure. To overcome the possibility of differential
intensity of treatment, diagnosis, or adverse event
reporting between groups, pill count enabled a more
objective assessment of adherence during the trial.
There are several mechanisms whereby a polypill
strategy may enhance adherence, which include ease
of prescription, packaged delivery, ease of taking,
and patient acceptability. This shows that physicians
from 5 different countries are willing to prescribe a
polypill to a post-MI population by involving them in
the trial, and at the end of the study, more patients
were taking the combination treatment than the
medications given separately.
The trial included patients with different socio-
economic background. It is noteworthy to mention
that in the case of Paraguay, most of the population
enrolled in the study was of the indigenous Guaranis,
with an underprivileged background. In this setting,
baseline adherence levels were extremely low (17% at
baseline), which is in line with previous ﬁndings (4).
As suggested by these results, it is in the setting of
LMIC in populations with lower use of indicated
medications that the effect of the FDC strategy could
have the most impact, due to lack of adherence,
accessibility, and affordability of CV medications.
IMPACT OF POLYPILL ON BP AND LDL-C. There
were no signiﬁcant differences between randomizedgroups for changes in systolic BP or LDL-C, in line
with other previous reports. The main reason for that
is the added beneﬁt of an increase in adherence in the
polypill group was effectively counter-balanced by
the use of other lipid-lowering and antihypertensive
drugs in the control group.
IMPLICATIONS OF FINDINGS AND FUTURE RESEARCH.
The FOCUS trial had several strengths in terms of
identifying the factors that impede adherence to CV
medications in secondary prevention, assessing
adherence with different methods, and dispensing
both the FDC and the 3 drugs given separately for
free. Our results support the potential usefulness
of a polypill-based care in secondary prevention,
particularly in patients with a previous MI. Com-
plexity of treatment and number of pills, as well as
depression, all of which tend to coexist in this pa-
tient population, impede adequate adherence to
guideline-recommended, effective CV pharmaco-
therapy. In the past 2 decades, the responsibility has
shifted from caregivers (as seen by the nearly universal
prescription rates at discharge) to patients taking
the prescribed medications. The reasons for non-
adherence are complex and fall into different cate-
gories as proposed by the World Health Organization
(socioeconomic, medication-related, condition-relat-
ed, health system-related, and patient-related factors)
(22). The reality is that nonadherence to secondary CV
medication has tremendous health impact and eco-
nomic costs. In fact, 37% of all MIs in the United States
in 2013 were recurrences, and, with this understand-
ing, strategies that improve adherence will have an
important effect onmitigating, at least in part, the CVD
burden.
We believe the FOCUS trial has included the use of
validated, direct, and indirect measures of adherence
that go beyond previous trials. Furthermore, FOCUS
has successfully identiﬁed the factors that weigh into
being nonadherent, mainly the level of depression,
complexity of treatment, and number of medications.
In the light of these results, these factors need to be
addressed by the different stakeholders in order to
provide effective strategies that improve medication
nonadherence.
The use of medications based on solid clinical ev-
idence has contributed substantially to reductions in
CV morbidity and mortality. Current guidelines
recommend concomitant use of aspirin, statin, and
BP-lowering agents in patients with a history of cor-
onary heart disease; yet, available data have contin-
uously shown that many patients in high-income
countries, and most in low-income countries, do not
receive such treatment long term. The results from
the FOCUS trial effectively show that FDC-based care
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Lack
of adherence to guideline-recommended, efﬁcacy-
proven CV medications after an acute MI is, in part,
responsible for the gap in secondary prevention.
COMPETENCY IN PATIENT CARE: In secondary
prevention following an acute MI, younger age,
depression, and following a complex drug treatment
are associated with a lower medication adherence,
whereas adherence is increased in patients with higher
levels of insurance coverage and social support. In
patients following an acute MI, a polypill strategy
signiﬁcantly increases adherence to medication.
TRANSLATIONAL OUTLOOK: Although this is a
short-term study, long-term evaluation of the polypill
strategy is necessary for a conﬁrmation of adherence
and clinical endpoints.
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2082achieves signiﬁcantly better rates of adherence than
when 3 drugs are given separately. The use of FDC
demonstrated good short-term safety and tolerability
and short-term risk factor reductions that were of
approximately the size expected from the additive
effects of the individual agents.
Larger, longer-term pragmatic trials assessing the
effect of an FDC strategy on clinical CV outcomes are
needed.
CONCLUSIONS
Compared with the 3 drugs given separately, the
use of a polypill strategy signiﬁcantly increases self-
reported and directly-measured medication adher-
ence for secondary prevention following an acute
MI.
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